Literature DB >> 12091468

Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain.

Thomas Toneff1, Liane Mende-Mueller, Ying Wu, Shin-Rong Hwang, Richard Bundey, Leslie M Thompson, Marie-Francoise Chesselet, Vivian Hook.   

Abstract

Proteolytic fragments of huntingtin (htt) in human lymphoblast cell lines from HD and control cases were compared to those in human HD striatal and cortical brain regions, by western blots with epitope-specific antibodies. HD lymphoblast cell lines were heterozygous and homozygous for the expanded CAG triplet repeat mutations, which represented adult onset and juvenile HD. Lymphoblasts contained NH(2)- and COOH-terminal htt fragments of 20-100 kDa, with many similar htt fragments in HD compared to control lymphoblast cell lines. Detection of htt fragments in a homozygous HD lymphoblast cell line demonstrated proteolysis of mutant htt. It was of interest that adult HD lymphoblasts showed a 63-64 kDa htt fragment detected by the NH(2)-domain antibody, which was not found in controls. In addition, control and HD heterozygous cells showed a common 60-61 kDa band (detected by the NH(2)-domain antibody), which was absent in homozygous HD lymphoblast cells. These results suggest that the 63-64 kDa and 60-61 kDa NH(2)-domain htt fragments may be associated with mutant and normal htt, respectively. In juvenile HD lymphoblasts, the presence of a 66-kDa, instead of the 63-64 kDa N-domain htt fragment, may be consistent with the larger polyglutamine expansion of mutant htt in the juvenile case of HD. Lymphoblasts and striatal or cortical regions from HD brains showed similarities and differences in NH(2)- and COOH-terminal htt fragments. HD striatum showed elevated levels of 50 and 45 kDa NH(2)-terminal htt fragments [detected with anti(1-17) serum] compared to controls. Cortex from HD and control brains showed similar NH(2)-terminal htt fragments of 50, 43, 40, and 20 kDa; lymphoblasts also showed NH(2)-terminal htt fragments of 50, 43, 40, and 20 kDa. In addition, a 48-kDa COOH-terminal htt band was elevated in HD striatum, which was also detected in lymphoblasts. Overall, results demonstrate that mutant and normal htt undergo extensive proteolysis in lymphoblast cell lines, with similarities and differences compared to htt fragments observed in HD striatal and cortical brain regions. These data for in vivo proteolysis of htt are consistent with the observed neurotoxicity of recombinant NH(2)-terminal mutant htt fragments expressed in transgenic mice and in transfected cell lines that may be related to the pathogenesis of HD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091468     DOI: 10.1046/j.1471-4159.2002.00940.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells.

Authors:  Ferdinando Squitieri; Vittorio Maglione; Sara Orobello; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2011-04-26       Impact factor: 3.575

2.  Native mutant huntingtin in human brain: evidence for prevalence of full-length monomer.

Authors:  Ellen Sapp; Antonio Valencia; Xueyi Li; Neil Aronin; Kimberly B Kegel; Jean-Paul Vonsattel; Anne B Young; Nancy Wexler; Marian DiFiglia
Journal:  J Biol Chem       Date:  2012-02-27       Impact factor: 5.157

3.  Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo.

Authors:  Robert O'Brien; Francesco DeGiacomo; Jennifer Holcomb; Akilah Bonner; Karen L Ring; Ningzhe Zhang; Khan Zafar; Andreas Weiss; Brenda Lager; Birgit Schilling; Bradford W Gibson; Sylvia Chen; Seung Kwak; Lisa M Ellerby
Journal:  J Biol Chem       Date:  2015-05-29       Impact factor: 5.157

Review 4.  The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review.

Authors:  R Walsh; E Storey; D Stefani; L Kelly; V Turnbull
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 5.  Studying polyglutamine diseases in Drosophila.

Authors:  Zhen Xu; Antonio Joel Tito; Yan-Ning Rui; Sheng Zhang
Journal:  Exp Neurol       Date:  2015-08-06       Impact factor: 5.330

6.  Effect of post-mortem delay on N-terminal huntingtin protein fragments in human control and Huntington disease brain lysates.

Authors:  Menno H Schut; Stefano Patassini; Eric H Kim; Jocelyn Bullock; Henry J Waldvogel; Richard L M Faull; Barry A Pepers; Johan T den Dunnen; Gert-Jan B van Ommen; Willeke M C van Roon-Mom
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

Review 7.  Pathogenesis and potential therapeutic application of stem cells transplantation in Huntington's disease.

Authors:  Sudeepto Saha; Manami Jayati Dey; Salman Khan Promon; Yusha Araf
Journal:  Regen Ther       Date:  2022-09-25       Impact factor: 3.651

8.  Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.

Authors:  Andreas Weiss; Ulrike Träger; Edward J Wild; Stephan Grueninger; Ruth Farmer; Christian Landles; Rachael I Scahill; Nayana Lahiri; Salman Haider; Douglas Macdonald; Chris Frost; Gillian P Bates; Graeme Bilbe; Rainer Kuhn; Ralph Andre; Sarah J Tabrizi
Journal:  J Clin Invest       Date:  2012-09-17       Impact factor: 14.808

Review 9.  Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.

Authors:  Maria Jimenez-Sanchez; Floriana Licitra; Benjamin R Underwood; David C Rubinsztein
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

Review 10.  From pathways to targets: understanding the mechanisms behind polyglutamine disease.

Authors:  Jonasz Jeremiasz Weber; Anna Sergeevna Sowa; Tina Binder; Jeannette Hübener
Journal:  Biomed Res Int       Date:  2014-09-21       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.